AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6352655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g ceftazidime twice daily for five days
Number of subjects: 166
Study 6352655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 g ceftazidime twice daily for five days
Number of subjects: 166
Study 6352655 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.00 g ceftazidime twice daily for five days
Number of subjects: 166
Study 31926918 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine 0.3 g twice daily
Number of subjects: 553
Study 31926918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study 30670262 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond oil (10 ml, two times daily for 30 days)
Number of subjects: 97
Study 30670262 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 97
Study 28629665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib monotherapy (5 mg twice daily)
Number of subjects: 1146
Study 28629665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib plus methotrexate (5 mg twice daily)
Number of subjects: 1146
Study 28629665 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab plus methotrexate (40 mg every other week)
Number of subjects: 1146
Study 26004087 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin (40mg/m², days 1-3)
Number of subjects: 60
Study 26004087 — intervention group
Group type: COMPARATOR
Intervention: Re-challenge with platinum doublet
Number of subjects: 60
Study 23090719 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 40
Study 23090719 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 40
Study 21735192 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day Letrozole (group 1)
Number of subjects: 67
Study 21735192 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/day Letrozole (group 2)
Number of subjects: 67
Study 19370533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel chemotherapy (1, 2, or 3 cycles)
Number of subjects: 69
Study 19370533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel chemotherapy (2 cycles)
Number of subjects: 69
Study 19370533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel chemotherapy (3 cycles)
Number of subjects: 69
Study 19370533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel chemotherapy
Number of subjects: 69
Study 16510768 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) 250 mg twice daily
Number of subjects: 22
Study 16510768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15585154 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorption (AP) group
Number of subjects: 90
Study 15585154 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF) group
Number of subjects: 90
Study 15585154 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (HD) group
Number of subjects: 90
Study 11214094 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly chloroquine prophylaxis
Number of subjects: 473
Study 11214094 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron and weekly folic-acid supplementation
Number of subjects: 473
Study 11214094 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management of malaria
Number of subjects: 473
Study 11214094 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 473
Study 9323688 — intervention group
Group type: EXPERIMENTAL
Intervention: FOSL-HN (fish oil/medium-chain triglyceride structured lipid)
Number of subjects: 20
Study 9323688 — intervention group
Group type: COMPARATOR
Intervention: O-HN (isonitrogenous, isocaloric formula)
Number of subjects: 20
Study 8498495 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (200 meq/day)
Number of subjects: 8
Study 2931096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8
Study 2931096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 8
Study 2931096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 8
Study 2931096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29391265 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF group (n = 18)
Number of subjects: 57
Study 29391265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (G‐CSF + NAC) (n = 19)
Number of subjects: 57
Study 29391265 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy group (n = 20)
Number of subjects: 57
Study 29391265 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF group
Number of subjects: 57
Study 29391265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 57
Study 29391265 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 57
Study 26926657 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention (test 1 and test 2 groups)
Number of subjects: 162
Study 26926657 — intervention group
Group type: COMPARATOR
Intervention: Control group (care from physician/nurses)
Number of subjects: 162
Study 26277873 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-1 block
Number of subjects: 10
Study 26277873 — intervention group
Group type: EXPERIMENTAL
Intervention: FI compartment block
Number of subjects: 10
Study 23665196 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (40 theta/beta training sessions)
Number of subjects: 23
Study 23665196 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological intervention (methylphenidate)
Number of subjects: 23
Study 20662342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional program (NUT) - 10 mg/day iron, 11 mg zinc three times a week, 10000 IU/week of vitamin A
Number of subjects: 54
Study 20662342 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GH) - 1.26 IU/kg/day (0.042 mg/kg/day)
Number of subjects: 54
Study 20662342 — intervention group
Group type: COMPARATOR
Intervention: Passive observation (OBS)
Number of subjects: 54
Study 18166090 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (SRP + HMT + TAT)
Number of subjects: 171
Study 18166090 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo
Number of subjects: 171
Study 16733739 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ferrous iron (fumarate)
Number of subjects: 301
Study 16733739 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ferrous iron (fumarate)
Number of subjects: 301
Study 16733739 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ferrous iron (fumarate)
Number of subjects: 301
Study 16733739 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ferrous iron (fumarate)
Number of subjects: 301
Study 16733739 — intervention group
Group type: COMPARATOR
Intervention: Control group (ferritin >70 microg/l)
Number of subjects: 301
Study 12628113 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 430
Study 12628113 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature
Number of subjects: 430
Study 12628113 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte count
Number of subjects: 430
Study 12628113 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of neutrophils
Number of subjects: 430
Study 12628113 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 430
Study 12628113 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rate
Number of subjects: 430
Study 12628113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex (male)
Number of subjects: 430
Study 12810974 — intervention group
Group type: EXPERIMENTAL
Intervention: Long segment Cotrel-Dubousset instrumentation (Group 1)
Number of subjects: 42
Study 12810974 — intervention group
Group type: EXPERIMENTAL
Intervention: Short segment Cotrel-Dubousset instrumentation (Group 2)
Number of subjects: 42
Study 12810974 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological recovery in incomplete paraplegics
Number of subjects: 42
Study 10586336 — intervention group
Group type: EXPERIMENTAL
Intervention: CHVP plus interferon (12 cycles in 18 months, interferon 5 MU TIW for 18 months)
Number of subjects: 131
Study 10586336 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine alone (25 mg/m2/d x 5 days for 6 cycles, then 20 mg/m2/day for 6 further cycles for 18 months)
Number of subjects: 131
Study 8596381 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplement (400 microgram/day)
Number of subjects: 62
Study 8596381 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic-acid-fortified foods (an additional 400 microgram/day)
Number of subjects: 62
Study 8596381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary folate (an additional 400 microgram/day)
Number of subjects: 62
Study 8596381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice
Number of subjects: 62
Study 8596381 — intervention group
Group type: COMPARATOR
Intervention: Control group (V)
Number of subjects: 62
Study 1947364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic blockade with 30 micrograms kg‐1 atropine administered by intravenous injection
Number of subjects: 0
Study 1947364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6357772 — intervention group
Group type: EXPERIMENTAL
Intervention: progabide (+/- 30 mg/kg/day)
Number of subjects: 20
Study 6357772 — intervention group
Group type: EXPERIMENTAL
Intervention: progabide
Number of subjects: 20
Study 6357772 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 31976819 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy home program (4 visits) during chemotherapy
Number of subjects: 48
Study 31976819 — intervention group
Group type: COMPARATOR
Intervention: General exercise during chemotherapy
Number of subjects: 48
Study 30816632 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper IUD
Number of subjects: 2629
Study 30816632 — intervention group
Group type: COMPARATOR
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 2629
Study 30816632 — intervention group
Group type: COMPARATOR
Intervention: Implant
Number of subjects: 2629
Study 30816632 — intervention group
Group type: COMPARATOR
Intervention: Norethisterone enanthate
Number of subjects: 2629
Study 30816632 — intervention group
Group type: EXPERIMENTAL
Intervention: All contraceptive methods
Number of subjects: 2629
Study 30816632 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2629
Study 28259141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 76
Study 28259141 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 76
Study 26983164 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen/paracetamol
Number of subjects: 173
Study 26983164 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiates
Number of subjects: 173
Study 26983164 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 173
Study 26983164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 173
Study 26983164 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin/pregabalin
Number of subjects: 173
Study 26983164 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported prescribing of acetaminophen/paracetamol and opiates
Number of subjects: 173
Study 26983164 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported prescribing of gabapentin
Number of subjects: 173
Study 25867579 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg daily for eight weeks)
Number of subjects: 80
Study 25867579 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-surgery group
Number of subjects: 80
Study 22119995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) chemotherapy
Number of subjects: 0
Study 22119995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy
Number of subjects: 0
Study 22119995 — intervention group
Group type: COMPARATOR
Intervention: Fatigue (assessed via PWB item)
Number of subjects: 0
Study 20629136 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day istradefylline
Number of subjects: 363
Study 20629136 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day istradefylline
Number of subjects: 363
Study 20629136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 17049679 — intervention group
Group type: EXPERIMENTAL
Intervention: NefTat and gp120(W61D) recombinant vaccine with AS02A adjuvant
Number of subjects: 84
Study 16296364 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia with amino acid infusion
Number of subjects: 30
Study 16296364 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia with amino acid infusion
Number of subjects: 30
Study 11979398 — intervention group
Group type: COMPARATOR
Intervention: Pramlintide (25 microg/h or 50 microg/h) administered via 5-hour intravenous infusion
Number of subjects: 102
Study 11979398 — intervention group
Group type: COMPARATOR
Intervention: Pramlintide (30, 100, or 300 microg) administered via subcutaneous injections 3 times daily
Number of subjects: 102
Study 9832919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed follow-up program
Number of subjects: 100
Study 9832919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 7851967 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR test for Mycobacterium tuberculosis
Number of subjects: 50
Study 7851967 — intervention group
Group type: COMPARATOR
Intervention: Control specimens (non-tuberculosis)
Number of subjects: 50
Study 7851967 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR test compared with Ziehl Neelsen staining and culture test
Number of subjects: 50
Study 2697448 — intervention group
Group type: EXPERIMENTAL
Intervention: Urotel postal urine cytology kit
Number of subjects: 184
Study 2697448 — intervention group
Group type: COMPARATOR
Intervention: Standard cytological method
Number of subjects: 184
Study 11859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY), 50 mg/kg on each of 4 successive days
Number of subjects: 49
Study 11859 — intervention group
Group type: COMPARATOR
Intervention: Procarbazine-antithymocyte globulin-CY
Number of subjects: 49
Study 11859 — intervention group
Group type: EXPERIMENTAL
Intervention: Second transplants attempted with original marrow donor or another HLA-identical sibling
Number of subjects: 49
Study 11859 — intervention group
Group type: EXPERIMENTAL
Intervention: Marrow transplantation
Number of subjects: 49
Study 29241082 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2400 mg/day
Number of subjects: 24
Study 29241082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29241082 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory Training (WM-training)
Number of subjects: 24
Study 28318450 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting session (FS)
Number of subjects: 21
Study 28318450 — intervention group
Group type: COMPARATOR
Intervention: Control session (CS)
Number of subjects: 21
Study 25741644 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at the SP6 point for 20 min during contractions
Number of subjects: 156
Study 25741644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 25741644 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 156
Study 25741644 — intervention group
Group type: COMPARATOR
Intervention: Acupressure, Placebo, Control
Number of subjects: 156
Study 21564310 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite swimmers with shoulder pain
Number of subjects: 50
Study 21564310 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite swimmers without shoulder pain
Number of subjects: 50
Study 21564310 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (healthy athletes)
Number of subjects: 50
Study 21068679 — intervention group
Group type: COMPARATOR
Intervention: Cold without warm-up
Number of subjects: 9
Study 21068679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold with warm-up
Number of subjects: 9
Study 21068679 — intervention group
Group type: COMPARATOR
Intervention: Ambient temperature without warm-up (AMB)
Number of subjects: 9
Study 21068679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature with warm-up (AMBWU)
Number of subjects: 9
Study 19010165 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 50
Study 19010165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17079539 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to neighborhood and community parks
Number of subjects: 1556
Study 17079539 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of parks within a half-mile radius
Number of subjects: 1556
Study 17079539 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of parks beyond a half-mile radius
Number of subjects: 1556
Study 17079539 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to specific park amenities (walking paths, running tracks, playgrounds, basketball courts)
Number of subjects: 1556
Study 17079539 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniparks, natural resource areas, walking paths, running tracks within a half-mile
Number of subjects: 1556
Study 17079539 — intervention group
Group type: EXPERIMENTAL
Intervention: Parks with streetlights and floodlights
Number of subjects: 1556
Study 17079539 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall presence of parks
Number of subjects: 1556
Study 17079539 — intervention group
Group type: EXPERIMENTAL
Intervention: Using the 3.0 metabolic equivalent cutpoint
Number of subjects: 1556
Study 14628394 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced cardiac life support (ACLS) recommendations
Number of subjects: 0
Study 14628394 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention via cardiopulmonary resuscitation
Number of subjects: 0
Study 14628394 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of patients' wishes regarding CPR initiation
Number of subjects: 0
Study 11559337 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid nasendoscope
Number of subjects: 56
Study 9288839 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) - 72 Gy/45 fractions/5 weeks
Number of subjects: 512
Study 9288839 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) - 70 Gy/35 fractions/7 weeks
Number of subjects: 512
Study 9288839 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF)
Number of subjects: 512
Study 9288839 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 512
Study 8298936 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Number of subjects: 137
Study 8298936 — intervention group
Group type: COMPARATOR
Intervention: Open appendicectomy
Number of subjects: 137
Study 3571741 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control therapy
Number of subjects: 29
Study 3571741 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral problem-solving therapy
Number of subjects: 29
Study 3571741 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 29
Study 2653297 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 50
Study 2653297 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 50
Study 2653297 — intervention group
Group type: COMPARATOR
Intervention: outpatient myelography
Number of subjects: 50
Study 2653297 — intervention group
Group type: COMPARATOR
Intervention: inpatient myelography
Number of subjects: 50
Study 31689780 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support interventions (16 sessions over 8 weeks, 2 times a week)
Number of subjects: 62
Study 31689780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 62
Study 28844201 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 6006
Study 28844201 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 6006
Study 26279339 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV (phase III lot 1)
Number of subjects: 712
Study 26279339 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV (phase III lot 2)
Number of subjects: 712
Study 26279339 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV (phase III lot 3)
Number of subjects: 712
Study 26279339 — intervention group
Group type: COMPARATOR
Intervention: CYD-TDV (phase II lot)
Number of subjects: 712
Study 26279339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 712
Study 23886205 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with light Thai massage (3 sessions with ginger and coconut oil over 1 week)
Number of subjects: 66
Study 23886205 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with light Thai massage
Number of subjects: 66
Study 23886205 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive care
Number of subjects: 66
Study 21844075 — intervention group
Group type: EXPERIMENTAL
Intervention: RenalGuard System with hydration using saline and N-acetylcysteine
Number of subjects: 292
Study 21844075 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate solution and N-acetylcysteine (control group)
Number of subjects: 292
Study 21844075 — intervention group
Group type: EXPERIMENTAL
Intervention: RenalGuard System
Number of subjects: 292
Study 19852790 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA (one round, 3 days)
Number of subjects: 65
Study 19852790 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA (seven rounds)
Number of subjects: 65
Study 19852790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 17909950 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary work rehabilitation (IWR) program
Number of subjects: 71
Study 12706319 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg acarbose t.i.d. for 6 weeks, followed by 100 mg acarbose t.i.d. for 12 weeks
Number of subjects: 0